[2026] BREDIS Healthcare Attends the Korean Neurological Association Spring Conference

On Saturday, April 4, 2026, BREDIS Healthcare participated in the 2026 Spring Conference of the Korean Neurological Association (KNA), taking the opportunity to explore the latest trends in biomarker analysis technology and introduce the company's core solutions. Through its exhibition booth and networking activities, BREDIS Healthcare showcased its ultrasensitive biomarker analysis platform, SIMOA, and its multiplex analysis technology, NULISA, highlighting their potential applications in research and clinical practice. SIMOA offers over 1,000 times the sensitivity of conventional ELISA, enabling quantification of biomarkers at the femtogram (fg/mL) level, while NULISA allows simultaneous analysis of multiple biomarkers in a single assay — effectively reducing both time and sample consumption. Researchers showed particular interest in the analysis of trace biomarkers that have traditionally been difficult to detect, with numerous inquiries about potential applications in real-world research and clinical settings. BREDIS Healthcare remains committed to strengthening its competitiveness in the field of precision biomarker analysis through continued conference participation and collaboration.